Real-world experience with obinutuzumab in difficult-to-treat myositis: concise report of a case series
- 25 August 2026
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (9)
Abstract
Objectives: Idiopathic inflammatory myopathy (IIM) is an orphan systemic disorder with muscular, cutaneous and pulmonary involvement. B cell–directed therapies, including rituximab, belimumab and chimeric antigen receptor T-cell (CAR-T), have shown promise in altering disease outcome. We report the benefit of obinutuzumab in difficult -to- treat myositis patients. Methods: The Northwell Rheumatology database was searched for obinutuzumab-treated patients (2019–24); five of them met 2017 EULAR/ACR classification criteria for IIM and were included in the analysis. Demographic, clinical, serological and imaging data were collected. Overall response was rated as complete, partial or no response based on clinical response and physician global assessment. Total improvement score was not calculated because data were collected retrospectively. Descriptive statistics were used for analyses. Results: Of five patients, two had antisynthetase syndrome, one dermatomyositis (DM) and two overlap myositis. Most patients failed at least three immunosuppressive agents. The reason for obinutuzumab use was rituximab allergy and worsening of interstitial lung disease (ILD) and myositis activity (3/5), arthritis (2/5) and severe rash (1/5 patients), despite rituximab. After obinutuzumab 80% of patients had overall improvement by 3–6 months. Respiratory status improved/stabilized in all ILD patients. Two patients required second obinutuzumab cycle: one for recurrence and another for persistent disease with B cell re-population. One was lost to follow-up after the second cycle and was deemed a non-responder. At last observation, 4/5 patients had achieved a complete response. No hypogammaglobulinaemia, significant infections or hospitalizations were observed. Conclusion: Obinutuzumab was safe and provided durable improvement in difficult-to-treat myositis patients with rituximab allergy, further highlighting targeting the B-cell pathway.Keywords
This publication has 20 references indexed in Scilit:
- Efficacy of obinutuzumab in two rituximab refractory cases of idiopathic inflammatory myopathies with severe interstitial lung diseaseAnnals of the Rheumatic Diseases, 2025
- Efficacy and Safety of Obinutuzumab in Active Lupus NephritisNew England Journal of Medicine, 2025
- Belimumab ameliorates symptoms and disease activity in patients with dermatomyositis and juvenile dermatomyositis refractory to standard therapy: A retrospective observational studyJournal of the American Academy of Dermatology, 2024
- CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-upNew England Journal of Medicine, 2024
- CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase SyndromeJAMA, 2023
- Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive DermatomyositisChest, 2023
- Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment OptionsNeurotherapeutics, 2022
- Obinutuzumab as treatment for ANCA-associated vasculitisRheumatology, 2021
- Lessons for rituximab therapy in patients with rheumatoid arthritisThe Lancet Rheumatology, 2020
- Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo‐phase trialArthritis & Rheumatism, 2012